Drug-induced liver injury with autoimmune features secondary to infliximab for ulcerative colitis
- 24 October 2023
- journal article
- research article
- Published by BMJ in BMJ Case Reports
- Vol. 16 (10) , e254272
Abstract
We present a patient with a drug-induced liver injury with autoimmune features as a result of infliximab therapy for ulcerative colitis. This is a rare but serious side effect in patients receiving this treatment which clinicians should consider in the event of liver function test derangement.Keywords
This publication has 11 references indexed in Scilit:
- DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humansDrug Discovery Today, 2016
- Infliximab-induced autoantibodies: a multicenter studyClinical Rheumatology, 2015
- Drug-induced liver injuryMedicine, 2015
- Inflammatory bowel disease: clinical aspects and treatmentsJournal of Inflammation Research, 2014
- Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported diseaseWorld Journal of Hepatology, 2014
- Liver Injury From Tumor Necrosis Factor-α Antagonists: Analysis of Thirty-four CasesClinical Gastroenterology and Hepatology, 2013
- Infliximab-related hepatitis: discussion of a case and review of the literatureInternal and Emergency Medicine, 2010
- Use of Tumor Necrosis Factor-α Inhibitors in Patients with Chronic Hepatitis B InfectionSeminars in Arthritis and Rheumatism, 2008
- Clinical Pharmacokinetics and Use??of??InfliximabClinical Pharmacokinetics, 2007
- Autoimmunhepatitis und Overlap-Syndrom: DiagnostikPraxis, 2002